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of Cytomegalovirus Infection and Disease in Patients
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Pau Montesinos,1 Jaime Sanz,1 Susana Cantero,1 Ignacio Lorenzo,1 Guillermo Martın,1
Silvana Saavedra,1 Javier Palau,1 Monica Romero,1 Alberto Montava,1 Leonor Senent,1
Jesus Martınez,1 Isidro Jarque,1 Miguel Salavert,2 Juan Cordoba,3 Lola Gomez,3
Shirley Weiss,1 Federico Moscardo,1 Javier de la Rubia,1 Luis Larrea,4
Miguel A. Sanz,1 Guillermo F. Sanz1There is no information on the efficacy and safety of anticytomegalovirus (CMV) prophylaxis with intrave-
nous ganciclovir or oral valganciclovir after unrelated cord-blood transplantation (UCBT). This issue was
addressed in 151 adults (117 CMV-seropositive) undergoing UCBT at a single institution. The first 38
CMV-seropositive recipients were assigned to receive prophylactic ganciclovir, and the next 79 were given
valganciclovir after engraftment. The cumulative incidence (CI) of CMV infection and disease was similar in
patients receiving valganciclovir or ganciclovir (59% versus 55%, P5 .59; and 9% versus 18%, P5 .33, respec-
tively). The toxicity profile and CI of nonrelapse mortality (CMV) and infection-related mortality did not dif-
fer between drugs. Patients receiving valganciclovir required fewer visits to the day hospital (P5.04). The CI
of CMV infection and disease in 34 CMV-seronegative recipients was 12% and 6%, indicating that tight CMV
monitoring is mandatory in this subset. The recipient’s CMV serostatus, acute and extensive chronic graft-
versus-host disease (aGVHD, cGVHD) were the main risk factors for CMV infection, and aGVHD for CMV
disease. This study suggests that prophylaxis with oral valganciclovir is as safe and effective as intravenous
ganciclovir for preventing CMV infection and disease after UCBT, but valganciclovir reduces the use of hos-
pital resources.
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6/j.bbmt.2009.03.002treatment at the earliest signs of infection based on
detection assays, such as DNA polymerase chain reac-
tion (PCR) or pp65 antigenemia (pp65 Ag), have per-
mitted major advances in the prevention and treatment
of CMV disease after allogeneic hematopoietic stem
cell transplant (HSCT) [1,2]. However, despite this
progress, CMV infection and disease remain a signifi-
cant cause of morbidity and mortality [1,2]. Patients
receiving unrelated cord blood transplantation
(UCBT) represent a subset with a high risk of CMV
infection and disease because of poor immune recon-
stitution [3]. Nevertheless, the incidence and outcome
of, and risk factors for, CMV infection and disease af-
ter UCBT have been scarcely addressed [4-8].
The knowledge of risk factors predicting CMV
infection and disease, such as the patient’s and donor’s
CMV serologic status [9-11] unrelated donor [12]
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pletion [4,10], allows the clinician to select the best
preventive strategy based on the patient’s risk status.
Strategies in high-risk patients include preemptive
therapy with intravenous ganciclovir as soon as they
become positive for CMV in the blood [14,15]; or in-
travenous ganciclovir prophylaxis initiated in all pa-
tients at the time of engraftment and continued until
day 100 after transplant [16,17]. The only randomized
study comparing both preventive strategies showed
a lower incidence of CMV infection and a similar inci-
dence of disease and survival, but a higher incidence of
neutropenia and fungal and bacterial infections in pa-
tients under prophylaxis [18]. Preemptive therapy with
ganciclovir is the strategy used most frequently to re-
duce the incidence of CMV disease after allogeneic
HSCT [2,19]. However, prophylaxis may be justified
in patients with a very high risk of CMV infection
and disease [1,2,11] such as CMV-seropositive recipi-
ents undergoing UCBT.
Valganciclovir, an oral prodrug of ganciclovir with
excellent bioavailability [20,21], has a similar efficacy
to intravenous ganciclovir for prophylaxis of CMV in-
fection in organ-solid transplant recipients [22-24].
Early studies also showed a similar efficacy to intrave-
nous ganciclovir as preemptive therapy in allogeneic
HSCT recipients [25-28]. Oral valganciclovir has the
potential to replace intravenous ganciclovir, making
outpatient care possible, which should provide more
comfort for the patient and reduce the use of hospital
resources. Oral valganciclovir may be especially valu-
able when prophylaxis for CMV infection and disease
is considered. Unfortunately, there is no information
on the efficacy and safety of valganciclovir as prophy-
laxis after allogeneic HSCT.
This study aimed to evaluate and compare the
efficacy, toxicity, and hospital resource use of prophy-
laxis of CMV infection and disease with intravenous
ganciclovir or oral valganciclovir in 2 consecutive co-
horts of CMV-seropositive adult patients undergoing
UCBT at a single center. The rates of CMV infection
and disease were also assessed in the group of CMV-
seronegative patients, in whom prophylaxis comprised
low-dose acyclovir. We also analyzed the characteris-
tics, outcome, and risk factors for CMV infection
and disease.MATERIAL AND METHODS
Patients and Transplant Characteristics
From May 1997 to July 2008, 151 adults with
hematologic malignancies underwent UCBT at Hos-
pital Universitario La Fe, Valencia, Spain. All patients
provided informed consent according to institutional
guidelines. The transplant protocols were approved
by the Research Ethics Board of the institutionaccording to the Declaration of Helsinki. Patients
undergoing UCBT with reduced-intensity condition-
ing (RIC) regimens were excluded from the study.
Donor-recipient matching was based on low-
resolution HLA typing for HLA-A and HLA-B, and
high resolution for HLA-DRB1. Early-disease stage
at UCBT was defined as chronic myelogenous leuke-
mia (CML) in the chronic phase, acute leukemia in first
or second complete remission (CR), myelodysplastic
syndrome (MDS) untreated or in CR, and lymphoma
in CR.
Preparative Regimens and GVHD Prophylaxis
The conditioning regimen comprised thiotepa
(TT), busulfan (Bu), cyclophosphamide (Cy), and an-
tithymocyte globulin (ATG) in 71 patients (47%)
[29], of whom 32 received horse ATG (Lymphoglobu-
lin, Merieux, Lyon, France) and 39 received rabbit
ATG (Thymoglobulin, Genzyme, Framingham,
MA). The conditioning regimen comprised TT, Bu,
fludarabine (Flu), and Thymoglobulin in 78 other pa-
tients (52%) [30]. One patient received Flu, TT, and
Lymphoglobulin as preparative regimen.
Acute GVHD (aGVHD) prophylaxis comprised
cyclosporine (CsA) plus prednisone in 79% of patients,
and CsA plus mycophenolate mofetil (MMF) in the
remaining 21%. aGVHD and chronic GVHD
(cGVHD) were graded according to criteria published
elsewhere [31,32].
Risk Stratification, Monitoring, and Diagnosis of
CMV Infection and Disease
CMV serology from the mother or cord blood unit
(CBU) and the recipient were assessed before UCBT.
None of the CBU or mothers was positive for immu-
noglobulin M (IgM) antibody to CMV. The CBU
was consideredCMV seronegative regardless of the se-
rostatus of the mother, and the risk stratification for
CMV infection and disease was based only on the pa-
tient’s CMV serostatus [33].
In CMV-seronegative (low-risk) patients, CMV
surveillance analysis was not performed systematically.
CMVsurveillancemonitoring of peripheral blood (PB)
samples from CMV-seropositive (high-risk) patients
was performed twice weekly from day 7 after transplant
to day 1100, every 15 days until day 1180, monthly
until day 1365, and weekly for patients taking more
than 15mg daily of prednisone for cGVHD.CMV sur-
veillance analysis was performed using pp65 Ag in PB
leukocytes in the first 60 CMV-seropositive patients
(51%), and plasma quantitative LightCycler-based
PCR (LC-PCR; Roche Diagnostics GmbH, Man-
nheim, Germany) [34] in the next 57 patients (49%).
Diagnosis of CMV viremia was made in the pres-
ence of 1 or more positive pp65 Ag assay (.1 infected
cell of 50,000 cells) or 1 or more positive PCR result
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fection was defined as the presence of CMV viremia,
CMV end-organ disease, or both. Diagnosis of CMV
disease was made using the standard clinical and
microbiologic criteria defined elsewhere [35].
Prophylactic Management and Treatment of
CMV Infection and Disease
Thirty-four CMV-seronegative patients (23%) re-
ceived prophylaxis with intravenous acyclovir (250
mg/m2 twice daily) from day –5 until day 130, fol-
lowed by oral acyclovir (400 mg 3 times daily) until
day 100 after transplant. CMV-seropositive patients
received prophylaxis with intravenous ganciclovir (first
cohort) or oral valganciclovir (second cohort). For the
first cohort of 38 CMV-seropositive patients (27%),
prophylaxis comprised intravenous acyclovir (500
mg/m2 3 times daily) from day –5 until engraftment,
which was followed until day 1100 by intravenous
ganciclovir (5 mg/kg daily from Monday to Friday)
and oral acyclovir (800 mg 3 times daily on Saturday
and Sunday). From October 2003, the second cohort
of 79 CMV-seropositive patients (52%) received pro-
phylaxis with intravenous acyclovir (500 mg/m2 3
times daily) from day –5 until engraftment, followed
by oral valganciclovir (900 mg once daily) until day
1120. All patients, including CMV-seronegative pa-
tients, received nonspecific intravenous immunoglob-
ulin (IgIV) at a dose of 0.5 g/kg weekly through day
1100 and then monthly during the first year after
transplant. All transfused products were irradiated
and depleted of leukocytes using blood collection sys-
tems with integrated high efficacy filters (diameter of
170-200 mm), but were not tested for CMV.
Once a positive CMVPCR or pp65 Ag test was de-
tected, preemptive first-line therapy was started with
intravenous ganciclovir 5mg/kg twice daily or oral val-
ganciclovir 900 mg twice daily (the latter only from
October 2003). Foscarnet 90 mg/kg twice daily was
used in patients with severe neutropenia. These sched-
ules were maintained for 14-21 days after the first of 2
consecutive negative tests of PB and were followed by
a maintenance dosage (every 24 hours) for 14-21 days
or until the completion of the originally scheduled
prophylaxis. When CMV disease was suspected or di-
agnosed, IgIV (0.5 g/kg every 48 hours) was added to
the preemptive schedule until resolution of symptoms.
Granulocyte-colony stimulating factor (G-CSF)
was given to maintain neutrophil count above 1.2 
109/L. Ganciclovir and valganciclovir were discontin-
ued temporarily and substituted with foscarnet if nec-
essary in patients with a neutrophil count\0.5-1 
109/L despite the administration of G-CSF. In
patients with renal failure, the doses of ganciclovir and
valganciclovir were reduced to 50% when creatinine
clearance was\70 mL/min and were reduced further
to 25% when creatinine clearance was\50 mL/min.Second-line treatment with intravenous foscarnet
was generally started in case of persistence of CMV
positive tests in PB after 3 to 4 weeks of first-line anti-
viral therapy, or in case of nonresponding/progressing
CMV disease.Study Definitions and Endpoints
The primary endpoint of the study was the inci-
dence of CMV infection. The secondary endpoints
were time to occurrence of CMV infection, time to oc-
currence and incidence of CMV disease, and time to
occurrence and incidence of a second episode of
CMV infection.
In patients with CMV infection or disease, the re-
sponse to treatment was monitored and evaluated us-
ing the pp65 Ag or PCR tests. Death, initiation of
second-line therapy, or persistently positive CMV
testing after 49 days of first-line antiviral therapy
were considered as treatment failure. Recurrent
CMV infection (second or later episode) was defined
as the development of a new positive CMV test occur-
ring after a 50-day interval free of CMV infection.
Another endpoint was the dose-limiting toxicities,
defined as the dose adjustment or withdrawal because
of related toxicity, of prophylaxis with ganciclovir
and valganciclovir. We also compared the use of hos-
pital resources per day of life during the first 365
days after UCBT in CMV-seropositive patients who
engrafted and survived more than 30 days. For this
purpose, we assessed the number of days the patients
received G-CSF injections, total number of hospitali-
zation days, number of hospitalization days for treat-
ment of CMV infection and disease, total number of
visits to the day hospital, and number of visits to the
day hospital for treatment or prophylaxis of CMV in-
fection and disease.
Overall survival (OS), nonrelapsemortality (NRM)
(all deaths occurring before relapse), and infection-re-
lated mortality (all deaths where fungal, viral, or bacte-
rial infection was a determinant contributing cause of
death and occurred before relapse) after UCBT were
also assessed.Data Collection and Prognostic Factors
Data were collected prospectively and registered.
Twenty patient and transplant characteristics were ex-
amined to establish their relationship with the devel-
opment of CMV infection and disease. Demographic
data and transplant characteristics included age, sex,
weight, underlying disease, disease stage, patient
CMV serostatus, degree of HLA mismatching; ABO
incompatibility, number of total nucleated, CD31,
CD41, CD81, and CD341 cells infused, conditioning
regimen, type of ATG, and aGVHD prophylaxis. The
rates of CMV infection and disease were assessed in
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ment of GVHD or cGVHD.Statistical Methods
Analysis was performed based on the intention-
to-treat principle. Fisher’s exact test, Mann-Whitney
U-test, and Student’s t-test were used to analyze differ-
ences in the distribution of variables between patient
subsets. The probabilities of CMV infection and dis-
ease, infection-related mortality, and NRM were esti-
mated by the cumulative incidence (CI) method (for
marginal probability) to take into account competing
risks, and these were compared using the Gray test
[36]. The characteristics selected for inclusion in the
multivariate analysis, using the Cox proportional haz-
ard model [37], were those for which there was some
indication of a significant association in the univariate
analysis (P\ .1), and, if available, those for which prior
studies had suggested a possible relationship, includ-
ing time-dependent development of GVHD. Overall
survival (OS) curves were plotted using the actuarial
method of Kaplan and Meier [38], and the differences
between curves were analyzed by the log-rank test [39].
The patient follow-up information was updated in
February 2009, and the median follow-up in survivors
was 40 months (range: 7-121 months). Except for the
CI method, all computations were performed using
BMDP statistical library programs (BMDP Statistical
Software, Los Angeles, CA) [40].RESULTS
Patients and Transplant Characteristics
Table 1 shows the patient and transplant charac-
teristics. Briefly, the median recipient age and weight
at transplant were 31 years (range: 15-52 years) and
70 kg (range: 40-112), respectively. The most frequent
underlying diseases were acute lymphoblastic leuke-
mia (35% of patients) and acute myelogenous leuke-
mia (AML) (32%). In 69% of patients, UCBT was
performed at an early disease stage. Donor-recipient
matching was as follows: 6/6 in 9 patients, 5/6 in 52 pa-
tients, 4/6 in 88 patients, and 3/6 in 2 patients. The
median number of nucleated, CD341, and CD31 cells
infused were 2.31  107/kg recipient’s body weight
(range: 0.98-5.83  107/kg), 1.21  105/kg (range:
0.08-0.09  105/kg), and 0.55  107/kg (range: 0.14-
1.61  107/kg), respectively. Diagnosis of CML and
use of lymphoglobulin in the preparative regimen
were more frequent in the first cohort of patients, re-
ceiving prophylaxis with ganciclovir (P\ .001). Pre-
parative regimens containing Flu and GVHD
prophylaxis with CsA plus MMF were more frequent
in the second cohort of patients, receiving prophylaxis
with valganciclovir (P\ .001).Incidence and Time of Diagnosis of CMV
Infection and Disease
Table 2 shows the CI of CMV infection, CMV dis-
ease, and second CMV infection in the entire cohort.
The CI of CMV infection was 47.3%, which occurred
at a median of 45 days after UCBT (range: 14-239
days). The CI of CMV disease was 10.8%, which oc-
curred comparatively late at a median of 145 days
(range: 35-355 days). The CI of a second recurrent
CMV infectionwas 20.8%,which occurred at amedian
of 151 days after UCBT (range: 64-372 days).Sites of CMV Disease
Sixteen patients experienced CMV disease: 7 pa-
tients under ganciclovir prophylaxis, 7 patients under
valganciclovir prophylaxis, and 2 CMV-seronegative
patients under acyclovir prophylaxis. The sites of
CMV disease were gastrointestinal in 8 patients, pneu-
monia in 6, retinitis in 1, and pancytopenia and fever in
1. Two patients developed gastrointestinal disease
without detectable CMV PCR or pp65 Ag in PB.
Five patients had recurrent CMV disease: 3 had pneu-
monia (one of them died from CMV pneumonia), 1
had gastrointestinal disease, and 1 had retinitis. Over-
all, 4 patients (3%) died from CMV disease (3 because
of pneumonia and 1 because of enteritis).Efficacy of Prophylaxis with Ganciclovir versus
Valganciclovir in CMV-Seropositive Patients
TheCI ofCMV infection at day1365 did not differ
significantlybetweenpatients takingganciclovir andval-
ganciclovir prophylaxis (55.3% versus 58.9%, P 5 .59)
(Figure 1A). In patients receiving ganciclovir for
CMV, infection occurred at a median of 37 days after
UCBT(range: 14-179days),whereas infectionoccurred
at a median of 50 days after UCBT (range:
14-239 days) in those receiving valganciclovir. The
rate of secondCMV infection did not differ significantly
between patients receiving prophylaxis with ganciclovir
or valganciclovir (23.7% versus 26.9%, P5 .78).
The CI of CMV disease did not differ between pa-
tients receiving ganciclovir prophylaxis and those re-
ceiving valganciclovir (18.4% versus 8.9%, P 5 .33)
(Table 2).Efficacy of Prophylaxis with Low-Dose Acyclovir
in CMV-Seronegative Patients
Four CMV-seronegative patients (CI of 11.8%)
developed CMV infection (on days 48, 55, 61, and
68). Two of these patients (CI of 5.9%) had concomi-
tant CMV disease on days 61 and 68 (one of them died
from CMV pneumonia).
Table 1. Patient and Transplant Characteristics According to CMV Prophylaxis
Characteristic
Total Acyclovir Ganciclovir Valganciclovir
PN (%) N (%) N (%) N (%)
Overall 151 (100) 34 (100) 38 (100) 79 (100)
Patient age (years)
Median (range) 31 (15-52) 30 (16-44) 32 (18-46) 31 (15-52) .85
15-24 42 (28) 12 (35) 9 (24) 21 (27)
25-34 52 (34) 10 (29) 13 (34) 29 (38)
35-44 46 (31) 12 (35) 13 (34) 21 (27)
$45 11 (7) 0 (0) 3 (8) 8 (10)
Sex
Male 95 (63) 21 (62) 23 (62) 51 (65) .90
Female 56 (37) 13 (38) 15 (38) 28 (35)
Diagnosis
Acute lymphoblastic leukemia 53 (35) 13 (38) 11 (29) 29 (37) <.001
Acute myelogenous leukemia 49 (32) 13 (38) 5 (13) 31 (39)
Chronic myelogenous leukemia 23 (15) 5 (15) 15 (39) 3 (4)
Lymphoma 11 (7) 2 (6) 1 (3) 8 (10)
Myelodysplastic syndrome 12 (8) 1 (13) 4 (10) 7 (9)
Other malignancy 3 (2) 0 (0) 2 (5) 1 (1)
Disease stage at UCBT
Early 104 (69) 25 (73) 28 (74) 51 (65) .49
Advanced 47 (31) 9 (27) 10 (26) 28 (35)
HLA compatibility
6/6 9 (6) 2 (6) 1 (3) 6 (8) .23
5/6 52 (35) 14 (41) 18 (47) 20 (25)
4/6 88 (58) 17 (50) 19 (50) 52 (66)
3/6 2 (1) 1 (3) 0 (0) 1 (1)
Preparative regimen
Bu/Cy-TT-Lymphoglobulin 32 (21) 10 (29) 22 (59) 0 (0) <.001
Flu-TT-Lymphoglobulin 1 (0) 0 (0) 1 (3) 0 (0)
Bu/CY-TT-Thymoglobulin 39 (26) 11 (32) 14 (38) 14 (18)
Bu/Flu-TT-Thymoglobulin 78 (52) 13 (39) 0 (0) 65 (82)
GVHD prophylaxis
CsA/prednisone 119 (79) 27 (79) 38 (100) 54 (68) <.001
CsA/mycophenolate 32 (21) 7 (21) 0 (0) 25 (32)
Acute GVHD
Grade 0-1-ii 117 (77) 24 (71) 32 (84) 61 (77) .33
Grade iii-iv 28 (19) 9 (26) 6 (16) 13 (17)
Not applicable 6 (4) 1 (3) 0 (0) 5 (6)
Chronic GVHD
No 48 (32) 11 (32) 8 (21) 29 (37) .66
Limited 22 (15) 6 (18) 5 (13) 11 (14)
Extensive 34 (22) 8 (24) 11 (29) 15 (19)
Not applicable 47 (31) 9 (26) 14 (37) 24 (30)
CMV monitoring method
pp65 Ag 60 (40) 0 (0) 38 (100) 22 (28) <.001
PCR 57 (38) 0 (0) 0 (0) 57 (72)
No monitoring 34 (23) 34 (100) 0 (0) 0 (0)
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; CsA, cyclosporine A; UCBT, unrelated cord blood transplant; Bu, busulphan;
Flu, fludarabine; TT, thiotepa; Cy, cyclophosphamide.
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Disease after UCBT
Factors predicting CMV infection and disease in
the entire cohort
The development of CMV infection was higher
in CMV-seropositive recipients (P\ .001), and there
was a trend to a higher rate in those who developed
extensive cGVHD (P 5 .06). Multivariate analysis
identified CMV serostatus of the recipient (hazard
ratio [HR], 8.77; 95% confidence interval [CI],
3.15-24.41; P\ .001), grade III–IV aGVHD (HR,
2.19; 95% CI, 1.18-4.09; P 5 .01), and extensivecGVHD (HR, 3.35; 95% CI, 1.24-9.00; P 5 .02),
as independent prognostic factors for CMV infec-
tion. The curves of CI of CMV infection depending
on the recipient CMV serostatus are showed in
Figure 1B. Concerning the risk factors for the devel-
opment of CMV disease in the overall cohort, a sta-
tistical trend was observed in patients developing
aGVHD (CI of 3.9% in patients with grade
0 aGVHD and 15.0% in those with grade I-IV;
P 5 .09). Multivariate analysis identified grade I–
IV aGVHD as an independent prognostic factor
for CMV disease (HR, 5.33; 95% CI, 1.19-23.87;
P 5 .008).
Table 2. Cumulative Incidence of First CMV Infection, SecondCMV Infection, and CMVDisease According to the Recipient’s CMV
Serostatus
First CMV Infection Second CMV Infection CMV Disease
Total of Patients CI at 100 CI at 365 CI at 100 CI at 365 CI at 100 CI at 365
Characteristic n n Days (%) Days (%) P No. Days (%) Days (%) P No. Days (%) Days (%) P
Overall 151 71 35.8 47.3 32 3.3 20.8 16 3.9 10.8
Recipient’s CMV serostatus
Seronegative 34 4 11.8 11.8 <.001 2 0.0 5.9 .06 2 5.9 5.9 .57
Seropositive 117 67 42.7 57.6 30 4.3 25.9 14 3.4 12.1
CI indicates cumulative incidence; CMV, cytomegalovirus.
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CMV-seropositive patients
Table 3 shows the results of the univariate analysis
of the prognostic factors for CMV infection and CMV
disease. The following characteristics were associated
with a higher rate of CMV infection: conditioning
regimen with lymphoglobulin (P5 .03) and the devel-
opment of grade III–IV aGVHD (P5 .001) and exten-
sive cGVHD (P5 .03). Multivariate analysis identified
grade III–IV aGVHD (HR, 2.60; 95% CI, 1.39-4.86;Figure 1. Cumulative incidence curves of CMV infection after UCBT.
(A) CI in CMV-seropositive patients according to CMV prophylaxis.
(B) CI according to the recipient CMV serostatus.P 5 .003), and extensive cGVHD (HR, 3.41; 95%
CI, 1.27-9.17; P5 .02), as independent prognostic fac-
tors for CMV infection.
The CI of CMV disease was greater for patients
developing grade I–IV aGVHD (P 5 .04), whereas
a statistical trend was observed in patients with exten-
sive cGVHD (P5 .07) (Table 3). Multivariate analysis
identified grade I–IV aGVHD as an independent
prognostic factor for CMV disease (HR, 10.28; 95%
CI, 1.34-78.61; P 5 .002).Response to Antiviral Treatment
Table 4 shows the response rate to first-line pre-
emptive therapy for episodes of first CMV infection.
Of the 67 episodes of first CMV infection presenting
without concomitant disease, 21 patients received
first-line therapy with ganciclovir, 37 with valganci-
clovir, 6 with foscarnet, and 2 with high-dose acyclo-
vir. The median time to CMV eradication was 15
days after the start of ganciclovir (range: 2-55 days)
and 14 days after the start of valganciclovir (range:
4-43 days). There were no differences in the rate of
CMV clearance at day 49 in patients treated with val-
ganciclovir (95% versus 81%, P 5 .17). Foscarnet
was started in 4 patients showing clinical resistance
to ganciclovir or valganciclovir (2 patients had
CMV infection resolution, 1 patient died from
CMV pneumonia, and 1 patient died from another
cause before eradication).
Of the 16 episodes of first CMV disease, 8 were
treated with ganciclovir (4 showed clinical resolution,
3 resolved after second-line treatment with foscarnet,
and 1 died fromCMV pneumonia), 7 with valganciclo-
vir (4 had clinical resolution, 1 resolved after second
line treatment with cidofovir, 1 died from CMV pneu-
monia despite second-line treatment with foscarnet,
and 1 died from CMV enteritis), and 1 with foscarnet
(showing clinical resolution).Toxicity of Antiviral Prophylaxis with
Ganciclovir versus Valganciclovir
Adverse events leading to treatment modification
were less frequent in the group of patients receiving
Table 3. Cumulative Incidence (CI) Rates of CMV Infection andDisease in CMV-Seropositive Patients According to the Patient and
Transplant Characteristics (Univariate Analysis)
Total of Patients
CMV Infection CMV Disease
Characteristic n n CI at 365 Days (%) P n CI at 365 Days (%) P
Overall 117 67 57.6 14 12.1
Patient age (years)
#30 52 27 52.2 .84 7 13.7 .48
>30 65 40 61.5 7 10.8
Sex
Male 74 44 59.9 .90 8 10.7 .99
Female 43 23 53.7 6 10.8
HLA compatibility
6/6 7 4 57.1 .81* 0 0.0 .38†
5/6 38 23 60.5 6 15.8
4/6 71 40 56.9 8 11.4
3/6 1 0 0.0 0 0.0
Preparative regimen‡‡
Cyclophosphamide 51 29 56.9 .48 9 17.6 .32
Fludarabine 66 38 58.5 5 7.7
Type of ATG
Lymphoglobulin 23 15 65.2 .03 4 17.4 .47
Thymoglobulin 94 52 55.8 10 10.8
GVHD prophylaxis
CsA/prednisone 92 54 58.7 .75 11 11.9 .62
CsA/mycophenolate 25 13 53.7 3 12.0
Acute GVHD
Grade 0 41 20 49.7 <.01‡ 1 2.4 .04§
Grade 1–ii 52 32 61.2 11 21.1
Grade iii-iv 19 15 78.9 2 10.5
Chronic GVHD¶
Absent or limited 53 31 58.8 .03 5 9.4 .07
Extensive 26 22 84.6 7 26.9
CMV monitoring test
pp65 Ag 60 33 55.0 .83 10 16.7 .33
PCR 57 34 61.0 4 7.2
CMV prophylaxis
Ganciclovir 38 21 55.3 .59 7 18.4 .33
Valganciclovir 79 46 58.9 7 8.9
CMV prophylaxis
and monitoring test
Ganciclovir/pp65 Ag 38 21 55.3 .63^ 7 18.4 .29^
Valganciclovir/pp65 Ag 22 12 54.6 .74** 3 13.6 .69**
Valganciclovir/PCR 57 34 61.0 .88†† 4 7.2 .64††
RIC indicates reduced-intensity conditioning; CsA, cyclosporinA; ATG, antithymocyte globulin;GVHD, graft-versus-host disease; CMV, cytomegalovirus.
*P HLA 6/6 versus HLA non-6/6 (57.6% versus 57.1%).
†P HLA 6/6 versus HLA non-6/6 (0.0% versus 12.9%).
‡P grade 0-ii versus grade iii-iv (56.3% versus 78.9%).
§P grade 0 versus grade 1-iv (2.4% versus 18.3%).
¶Analysis performed in patients surviving more than 100 days after UCBT.
^P ganciclovir/pp65 Ag versus valganciclovir/PCR.
**P ganciclovir/pp65 Ag versus valganciclovir/pp65 Ag.
††P valganciclovir/pp65 Ag versus valganciclovir/PCR.
‡‡Cyclophospamide-based: Bu/Cy-TT-ATG, Fludarabine: Bu/Flu-TT-ATG and Flu-TT-ATG.
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valganciclovir, but these differences were not signifi-
cant (3% versus 9%, P5 .27). In the ganciclovir group,
1 patient required dose adjustment because of renal
toxicity, and in the valganciclovir group, 7 patients
were switched temporarily to foscarnet because of neu-
tropenia. In addition, 5 patients of the valganciclovir
group (7%) were switched temporarily to ganciclovir
prophylaxis because of the impossibility of oral intake.
None of the patients developed secondary graft failure
after starting valganciclovir or ganciclovir.Hospital Resources Use during the First Year
after UCBTAccording to CMV Prophylaxis
One-hundred thirty patients were entered in this
analysis (Table 5). The cohort of patients receiving gan-
ciclovir prophylaxis spent 4.8%more of their days of life
during thefirst year in a dayhospital thandidpatients re-
ceiving valganciclovir prophylaxis (P5 .04). This differ-
encewas becauseof an increasednumberof days spent in
a day hospital receiving intravenous ganciclovir (P
\.001). Patients under ganciclovir prophylaxis also
Table 4. Response to Preemptive Therapy for CMV Infection
First-Line Preemptive Therapy
Ganciclovir Valganciclovir Foscarnet
Response n (%) n (%) P* n (%)
Total of patients 21 (100) 37 (100) 6 (100)
CMV eradication at day 21 12 (57) 22 (59) .87 2 (33)
CMV eradication at day 49 17 (81) 35 (95) .17 4 (66)
Change to second line 2 (10) 2 (5) .65 1 (17)
Death before eradication 1 (5) 0 (0) .40 1 (17)
CMV indicates cytomegalovirus.
*P compares preemptive therapy with ganciclovir versus valganciclovir.
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CMV infection and disease (P5 .005).
The percentage of patients requiring G-CSF after
engraftment to maintain neutrophil count above 1.2
109/L was significantly lower in CMV-seronegative
patients, compared with those patients receiving pro-
phylaxis with ganciclovir or valganciclovir (P 5
.008). The mean number of days the patients received
G-CSF therapy did not differ between the ganciclovir,
valganciclovir, and acyclovir prophylaxis groups.
Outcomes after UCBTAccording to CMV
Serostatus and CMV Prophylaxis
OS, NRM, and infection-related mortality rates at
day 1180 did not differ significantly between CMV-
seronegative (62%, 32%, and 21%, respectively) and
CMV-seropositive patients (61%, 32%, and 25%, re-
spectively; P5 .66, P5 .91 and P5 .89, respectively).
The same pattern was observed for patients receiving
valganciclovir (61%, 30%, and 24%, respectively) or
ganciclovir prophylaxis (61%, 37%, and 26%,
respectively;P5 .66,P5 .87 andP5 .85, respectively).
Figure 2 depicts the curves of the CI of infection-
related mortality according to CMV serostatus of the
recipients and prophylaxis of CMV infection in
CMV-seropositive patients. The distribution of causes
of fatal infection in patients under acyclovir, ganciclo-
vir, and valganciclovir prophylaxis was as follows: bac-
terial infection (9% versus 47% versus 39%,
respectively, P 5 .08); fungal infection (43% versus
13% versus 25%, respectively, P 5 .31); viruses and
other opportunistic pathogens (43% versus 7% versus
25%, respectively, P5 .17); and clinical infectionwith-
outmicrobiologic isolates (5%versus 33%versus 11%,
respectively, P5 .20).DISCUSSION
This study suggests that oral valganciclovir has
similar efficacy and toxicity as intravenous ganciclovir
in preventing CMV infection and disease in CMV-
seropositive adult patients undergoing UCBT. The
use of oral valganciclovir significantly reduced the
use of hospital resources. Both drugs appear to delayand reduce the expected incidence of CMV infection
and disease after UCBT without increasing the infec-
tion-related mortality and NRM.
CMV-seropositive patients undergoing UCBT
present with known risk factors for CMV infection,
such as CMV-seronegative donors [41], poor and de-
layed recovery of cellular immunity [3], and unrelated
donors [12], and they should be considered a target
population for an effective prophylaxis against CMV.
Three studies of CMV-seropositive patients undergo-
ing UCBT who did not receive prophylaxis found
a high incidence of CMV infection, ranging from
70% to 100% at day1100, along with an early presen-
tation [5,6,8]. In our study, we found a 41% incidence
of CMV infection in CMV-seropositive patients on
day 1100. Of note, all patients had received ATG
and half of them had received Flu for conditioning,
which are recognized risk factors for CMV infection
[2]. A study by Walker et al. [4], in which prophylaxis
for CMV-seropositive patients comprised high-dose
acyclovir, reported a 50% rate of CMV infection at
day 1180 in CMV-seropositive patients, a rate that
is similar to that observed at day 1180 in our study.
These similar incidences of CMV infection can be ex-
plained by the higher proportion of CMV-
seronegative patients in the study by Walker et al,
but also by the efficacy of prophylaxis with high-dose
acyclovir.
The incidence ofCMVdisease afterUCBTobserved
at day 1180 in the overall series (CMV-seropositive
and -seronegative patients) in our study (6%) is similar
to that reported by Walker et al. [4] (6%). However,
using preemptive therapy, Matsumura et al. [8] re-
ported a 16% incidence of CMV disease at day 1100
in a series of 140 UCBT recipients. In our series,
CMV disease appeared after day 1100 in a high pro-
portion of CMV-seropositive recipients (89%), with
a median interval of 145 days. This finding is consis-
tent with previous studies and emphasizes that CMV
prophylaxis can lead to a delayed recovery of CMV-
specific T cell immunity [42].
To our knowledge, our study is the first to analyze
the efficacy and toxicity of oral valganciclovir prophy-
laxis for CMV infection and disease after allogeneic
HSCT and is the first to compare oral valganciclovir
with intravenous ganciclovir for this purpose. For
this comparison, however, we acknowledge some lim-
itations. We compared 2 consecutive historic cohorts
of CMV-seropositive patients and used 2 different
methods for CMV monitoring. Most of the valganci-
clovir cohort was monitored using CMV PCR,
whereas the cohort receiving intravenous ganciclovir
was monitored only with pp65 Ag. Our results suggest
that oral valganciclovir can prevent CMV infection
and disease after UCBT with the same efficacy as in-
travenous ganciclovir. When the analysis was re-
stricted to patients monitored by the pp65 Ag assay,
Table 5. Hospital Resources Use during the First Year after UCBTAccording to CMV Prophylaxis
CMV Prophylaxis
Hospital resource Ganciclovir (n 5 31) Valganciclovir (n 5 71) P† Acyclovir (n 5 33) P‡
% of days in inpatient hospital (range)* 48.5 (9.6-100) 42.9 (7.8-100) .68 42.0 (9.6-100) .89
% of days in inpatient hospital for CMV therapy (range)* 3.2 (0.0-30.9) 1.4 (0.0-38.6) .005 2.0 (0.0-22.2) .33
% of days in day hospital (range)* 14.9 (0.0-59.2) 10.1 (0.0-21.5) .04 8.7 (0.0-18.3) .08
% of days in day hospital for CMV therapy (range)* 6.8 (0.0-21.9) 0.1 (0.0-2.9) <.001 0.2 (0.0-3.8) .09
% of days receiving G-CSF (range)* 28.3 (3.0-94.0) 21.2 (0.8-73.3) .68 21.3 (0.7-95.0) .55
Number of patients requiring G-CSF after engrafment (%) 19 (61.3) 42 (59.1) .83 11 (33.3) .008
CMV indicates cytomegalovirus; G-CSF, granulocyte colony stimulating factor.
*Percentage of days of life during the first 365 days after UCBT; the analysis was performed only in patients surviving more than 30 days after UCBT.
†P compares valganciclovir versus ganciclovir.
‡P compares Acyclovir versus ganciclovir and valganciclovir together.
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served in both cohorts. Nevertheless, because of the
study design, we have to be cautious in the interpreta-
tion of data.
A major concern for the use of valganciclovir pro-
phylaxis after HSCT is the associated myelotoxicity
that can jeopardize the transplant outcome, especially
in UCBT, which is characterized by a prolonged mye-
losuppression [3] and an elevated risk of infection [7].
However, we observed no differences in the require-
ments for G-CSF and rates of infection-related
mortality, NRM, and OS after UCBT in patients re-
ceiving valganciclovir prophylaxis compared with
those receiving intravenous ganciclovir. It has been
speculated that oral valganciclovir could avoid the
use of intravenous antiviral agents that require either
hospitalization or frequent outpatient visits [27]. Our
study show that the use of oral valganciclovir signifi-
cantly reduced hospital resource use compared with
intravenous ganciclovir.
Despite the use of preemptive therapy, CMV-
seropositive patients undergoing allogeneic HSCT
from unrelated donors or those receiving a T cell-
depleted graft still have a higher mortality compared
with CMV-seronegative recipients grafted from
a CMV-seronegative donor [11,43]. In our study, the
rates of OS, NRM, and infection-related mortality
were similar in CMV-seropositive and CMV-seronega-
tive patients, suggesting that prophylaxis with either
intravenous ganciclovir or oral valganciclovir may over-
come the survival disadvantage of CMV-seropositive
patients in the setting of UCBT. Nevertheless, a lower
percentage of CMV-seronegative patients required
G-CSF after engraftment to maintain neutrophil count
above 1.2  109/L. Perhaps in relation with the myelo-
toxicity of the prophylaxis with ganciclovir and valgan-
ciclovir, CMV-serpositive patients had a trend toward
higher rates of bacterial fatal infections.
The incidence of CMV infection and disease in
CMV-seronegative patients in our study was higher
than in previous reports of UCBT [4,5]. Because of
the extremely low prevalence of CMV DNA-positiveCBUs among CMV IgM-negative CBUs using PCR
techniques (0.5%) [44], it is improbable that CMV in-
fection was acquired through the CBU. Therefore,
transfusion of blood products, even filtered-leukocyte
reduced products, is the most likely route for CMV
primo-infection. Unless additional studies confirm
that filtered leukocyte-reduced blood is equivalent to
CMV-seronegative blood products to avoid the trans-
mission of CMV, as has been suggested [45], it would
be reasonable to provide CMV-seronegative blood
products for all CMV-seronegative recipients of
UCBT. In addition, given the risk of early and aggres-
sive CMV disease observed, strict CMV surveillance is
mandatory for CMV-seronegative recipients.
The efficacy of preemptive therapy for CMV infec-
tion inUCBThas been scarcely addressed, and there are
no data on the use of oral valganciclovir. With intrave-
nous ganciclovir, the response rates to preemptive ther-
apy in UCBT range from 63% to 74% [4,46]. Within
the context of other stem cell sources, preemptive ther-
apy using oral valganciclovir seems to be at least as effec-
tive as intravenous ganciclovir for the treatment ofCMV
infection [25-27]. A preliminary report from a random-
ized trial in101patients undergoingdifferent typesof al-
logeneicHSCT showed similar rates of CMV clearance
after 28 days of intravenous ganciclovir or oral valganci-
clovir (54% and 64%, respectively) [28].We found sim-
ilar rates in UCBT recipients after 21 days of
intravenous ganciclovir (57%) and oral valganciclovir
(59%), indicating that oral valganciclovir can be as effec-
tive than intravenous ganciclovir for preemptive therapy
of CMV infection after UCBT.
Our study shows that CMV serostatus of the recip-
ient, and aGVHD were the main risk factors for CMV
infection after UCBT, confirming the results of previ-
ous studies [4,5]. In CMV-seropositive recipients, the
development of extensive cGVHD and aGVHD
were associated with a higher incidence of CMV infec-
tion, as suggested previously by Matsumura et al. [8].
In conclusion, our study suggests that prophylaxis
with oral valganciclovir is as effective as intravenous
ganciclovir for reducing the incidenceofCMVinfection
Figure 2. Cumulative incidence curves of infection-related mortality
after UCBT. (A) CI in CMV-seropositive patients according to CMV pro-
phylaxis. (B) CI according to the recipient CMV serostatus.
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Oral valganciclovir has an acceptable toxicity profile
and leads to a significant reduction of the use of hospital
resources when compared with intravenous ganciclovir.
Well-designed clinical trials to compare the efficacy
and toxicity of anti-CMV prophylaxis and preemptive
strategies with oral valganciclovir or other antiviral
drugs after UCBT are required.ACKNOWLEDGMENTS
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